Food and drug companies have expressed optimism, but the new health secretary and his MAHA movement will likely make waves.

RFK Jr. will run the federal agency responsible for drug approvals, Medicare and Medicaid, vaccination guidance, ...

As the Q4 2024 pharma earnings period rolls on through the first month of President Donald Trump’s second term, executives ...

Welcome to the Wall Street Week newsletter, bringing you stories of capitalism about things you need to know, but even more ...

Pfizer CEO has met with the new administration and believes Trump and RFK Jr. are going to be net positives for the health ...

Pfizer CEO Albert Bourla revealed to stakeholders this week that the rendezvous took place in December, a few weeks after RFK Jr was nominated to head the Department of Health and Human Services ...

Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.

Pfizer CEO Albert Bourla said there are "opportunities that probably outweigh the risks" of the Trump administration's "radical" changes.

While the exact date of the meeting was not disclosed, Bourla said he and the health secretary nominee chatted civilly, conversing on topics they agreed on rather than straying to more divisive ...

In an interview on CNBC’s Mad Money, Dr. Albert Bourla said Pfizer (PFE) is focusing on business development to create shareholder value. “We ...

Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as ...